Loading organizations...
§ Private Profile · New Haven, CT, USA
Medical technology company developing the BioBrace bioinductive implant for orthopedic soft tissue repair and regeneration.
Based in New Haven, Connecticut, Biorez is a medical device company that develops regenerative technology and bioinductive implants for orthopedic and sports medicine applications. The firm's primary product is the BioBrace scaffold, an FDA-cleared biocomposite implant designed to reinforce soft tissue repairs and promote natural healing in tendons and ligaments. This technology utilizes a porous collagen sponge for cell infiltration alongside a bioresorbable polymer for strength, which naturally resorbs over a two-year period. Prior to its exit, the enterprise raised $35.79 million in venture funding from backers including Connecticut Innovations and New York Angels. Advised by Canaccord Genuity, the business was acquired by ConMed Corporation in August 2022 for $85 million in upfront cash and up to $165 million in growth-based earnouts, representing a total potential valuation of $250 million. Biorez was founded in 2016 by Kevin Rocco.
Biorez has raised $16.0M across 4 funding rounds.
Biorez has raised $16.0M in total across 4 funding rounds.
Biorez has raised $16.0M across 4 funding rounds. Most recently, it raised $4.0M Seed in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2020 | $4M Seed | NEW York Angels | 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital, Brainchild Holdings, Priztker/vlock Family Office, The Vertical Group | Announced |
| Mar 1, 2018 | $2M Series C | — | 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital | Announced |
| Jan 6, 2014 | $5M Venture Round | Connecticut Innovations, Launch Capital | Dane Miller, Richard B. Emmitt | Announced |
| Jan 1, 2014 | $5M Series U | Connecticut Innovations, Launch Capital | 5AM Ventures, Access Biotechnology, Canaan Partners, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital, Dane Miller, The Vertical Group | Announced |
Biorez is a medical technology company specializing in orthopedics, developing the BioBrace scaffold, a bioinductive implant that reinforces tendon and ligament repairs while promoting soft tissue regeneration.[1][2][3] It serves surgeons and healthcare providers in specialties like orthopedics, addressing the challenge of weak soft tissue healing post-surgery by enabling cellular infiltration, vascular ingrowth, and gradual load-sharing as the implant resorbs.[1][3] Founded in 2016 in New Haven, Connecticut, Biorez raised $35.79M before being acquired by CONMED Corporation in August 2022 for a valuation between $85M and $250M, integrating its technology into CONMED's portfolio of surgical devices.[1][2]
Now operating as a CONMED company, Biorez continues to advance BioBrace, which is FDA-cleared in multiple sizes for minimally invasive procedures, demonstrating strong growth momentum through acquisition and commercialization in the soft tissue repair market.[1][2]
Biorez, formerly known as Soft Tissue Regeneration, was founded in 2016 in New Haven, Connecticut, by Kevin Rocco, who serves as President, CEO, and Founder.[1][2] The company emerged from a focus on innovating soft tissue regeneration in orthopedics, pioneering the BioBrace implant to overcome limitations in traditional repairs where tissues often fail to heal robustly.[1][3]
Early traction built around BioBrace's unique biocomposite design—a porous collagen sponge combined with bioresorbable polymer microfilaments—leading to FDA clearance and partnerships like with XVIVO for technology validation.[3] A pivotal moment came in August 2022 with its acquisition by CONMED, marking validation of its technology and enabling scaled distribution through CONMED's global surgical network.[1][2]
Biorez stands out in the medtech space through BioBrace's engineered features:
Biorez rides the wave of regenerative medicine and bioinductive implants, capitalizing on rising demand for solutions that enhance soft tissue outcomes in orthopedics amid an aging population and sports injury surge.[1][3] Timing aligns with advances in biomaterials, where bioresorbable scaffolds outperform autografts or synthetics by reducing re-tear rates and complications.[3][4]
Market forces like FDA's support for innovative devices and CONMED's dominance in minimally invasive surgery favor Biorez, influencing the ecosystem by setting a standard for hybrid collagen-polymer tech that could expand to general surgery or gynecology.[1][2] Its acquisition underscores investor confidence in orthobiologics, pushing competitors toward similar regenerative approaches.
Biorez's BioBrace positions it for expansion within CONMED, potentially into new indications like rotator cuff repairs or ACL reinforcements, driven by clinical data on resorption and tissue restoration.[1][3] Trends in personalized orthopedics and biologics will shape its path, with AI-optimized scaffolds or combo therapies on the horizon.
As CONMED evolves its portfolio, Biorez could amplify influence in global medtech, redefining soft tissue repair from reinforcement to true regeneration—echoing its founding promise to advance healing beyond conventional limits.[2][4]
Biorez has raised $16.0M in total across 4 funding rounds.
Biorez's investors include New York Angels, 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital, Brainchild Holdings, Priztker/Vlock Family Office, The Vertical Group.